Related references
Note: Only part of the references are listed.A Summary on the Genetics of Systemic Lupus Erythematosus, Rheumatoid Arthritis, Systemic Sclerosis, and Sjogren's Syndrome
Lourdes Ortiz-Fernandez et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2023)
Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis
David Jayne et al.
ANNALS OF THE RHEUMATIC DISEASES (2022)
High Systemic Type I Interferon Activity Is Associated With Active Class III/IV Lupus Nephritis
Taro Iwamoto et al.
JOURNAL OF RHEUMATOLOGY (2022)
Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis
Melissa Northcott et al.
LUPUS SCIENCE & MEDICINE (2022)
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials
Edward M. Vital et al.
ANNALS OF THE RHEUMATIC DISEASES (2022)
Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus
Richard A. Furie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Variety of endosomal TLRs and Interferons (IFN-α, IFN-β, IFN-γ) expression profiles in patients with SLE, SSc and MCTD
A. Paradowska-Gorycka et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2021)
Prevalence of Systemic Lupus Erythematosus in the United States: Estimates From a Meta-Analysis of the Centers for Disease Control and Prevention National Lupus Registries
Peter M. Izmirly et al.
ARTHRITIS & RHEUMATOLOGY (2021)
Study of Tofacitinib in Refractory Dermatomyositis: An Open-Label Pilot Study of Ten Patients
Julie J. Paik et al.
ARTHRITIS & RHEUMATOLOGY (2021)
Partial Protection From Lupus-Like Disease by B-Cell Specific Type I Interferon Receptor Deficiency
Emma J. Keller et al.
FRONTIERS IN IMMUNOLOGY (2021)
JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study
Tom Le Voyer et al.
RHEUMATOLOGY (2021)
Identification of 38 novel loci for systemic lupus erythematosus and genetic heterogeneity between ancestral groups
Yong-Fei Wang et al.
NATURE COMMUNICATIONS (2021)
Genetic Polymorphisms in Genes Involved in the Type I Interferon System (IFIH1/MDA-5, TNFAIP3/A20, and STAT4): Association with SLE Risk in Egyptian Children and Adolescents
Mohamed M. Zedan et al.
JOURNAL OF INFLAMMATION RESEARCH (2021)
Type I interferon signaling mediates Mycobacterium tuberculosis-induced macrophage death
Li Zhang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2021)
The baseline interferon signature predicts disease severity over the subsequent 5 years in systemic lupus erythematosus
Lloyd Mai et al.
ARTHRITIS RESEARCH & THERAPY (2021)
Safety and tolerability of anifrolumab, a monoclonal antibody targeting type I interferon receptor, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study
Yoshiya Tanaka et al.
MODERN RHEUMATOLOGY (2020)
Safety and tolerability of sifalimumab, an anti-interferon-α monoclonal antibody, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study
Tsutomu Takeuchi et al.
MODERN RHEUMATOLOGY (2020)
Immunological pathogenesis and treatment of systemic lupus erythematosus
Lu Pan et al.
WORLD JOURNAL OF PEDIATRICS (2020)
IFN-alpha kinoid in systemic lupus erythematosus: results from a phase IIb, randomised, placebo-controlled study
Frederic A. Houssiau et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
Eric F. Morand et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The activation trajectory of plasmacytoid dendritic cells in vivo during a viral infection
Abdenour Abbas et al.
NATURE IMMUNOLOGY (2020)
Study protocol for the international Systemic Lupus Erythematosus Prospective Observational Cohort Study (SPOCS): understanding lupus and the role of type I interferon gene signature
Edward R. Hammond et al.
BMJ OPEN (2020)
Type I Interferon (IFN)-Regulated Activation of Canonical and Non-Canonical Signaling Pathways
Candice Mazewski et al.
FRONTIERS IN IMMUNOLOGY (2020)
Neutrophil and lymphocyte counts are associated with different immunopathological mechanisms in systemic lupus erythematosus
Bobby Kwanghoon Han et al.
LUPUS SCIENCE & MEDICINE (2020)
The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis
Christel Wilkinson et al.
ARTHRITIS RESEARCH & THERAPY (2020)
Adults with systemic lupus exhibit distinct molecular phenotypes in a cross-sectional study
Joel M. Guthridge et al.
ECLINICALMEDICINE (2020)
Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus
Richard Furie et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Identification of distinctive interferon gene signatures in different types of myositis
Iago Pinal-Fernandez et al.
NEUROLOGY (2019)
Association between changes in gene signatures expression and disease activity among patients with systemic lupus erythematosus
Michelle Petri et al.
BMC MEDICAL GENOMICS (2019)
Sex and Pubertal Differences in the Type 1 Interferon Pathway Associate With Both X Chromosome Number and Serum Sex Hormone Concentration
Kate Webb et al.
FRONTIERS IN IMMUNOLOGY (2019)
Interferon signaling in cancer. Non-canonical pathways and control of intracellular immune checkpoints
Diana Saleiro et al.
SEMINARS IN IMMUNOLOGY (2019)
JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis
Leandro Ladislau et al.
BRAIN (2018)
Higher activation of the interferon-gamma signaling pathway in systemic lupus erythematosus patients with a high type I IFN score: relation to disease activity
Manman Liu et al.
CLINICAL RHEUMATOLOGY (2018)
Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial
Mark C. Genovese et al.
LANCET (2018)
Urinary cytokines and mRNA expression as biomarkers of disease activity in lupus nephritis
B. Jakiela et al.
LUPUS (2018)
Identification of new type I interferon-stimulated genes and investigation of their involvement in IFN-β activation
Xiaolin Zhang et al.
PROTEIN & CELL (2018)
Interferon activation in primary Sjogren's syndrome: recent insights and future perspective as novel treatment target
Iris L. A. Bodewes et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2018)
Type I IFN signature in childhood-onset systemic lupus erythematosus: a conspiracy of DNA- and RNA-sensing receptors?
M. Javad Wahadat et al.
ARTHRITIS RESEARCH & THERAPY (2018)
Pathways of impending disease flare in African-American systemic lupus erythematosus patients
Melissa E. Munroe et al.
JOURNAL OF AUTOIMMUNITY (2017)
A Novel Human Systemic Lupus Erythematosus Model in Humanised Mice
Merry Gunawan et al.
SCIENTIFIC REPORTS (2017)
The Biomarkers of Lupus Disease Study: A Bold Approach May Mitigate Interference of Background Immunosuppressants in Clinical Trials
Joan T. Merrill et al.
ARTHRITIS & RHEUMATOLOGY (2017)
The Incidence and Prevalence of Systemic Lupus Erythematosus in New York County (Manhattan), New York: The Manhattan Lupus Surveillance Program
Peter M. Izmirly et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus
Richard Furie et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Human pDCs display sex-specific differences in type I interferon subtypes and interferon α/β receptor expression
Susanne M. Ziegler et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2017)
A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-alpha) in patients with systemic lupus erythematosus (ROSE)
Kenneth C. Kalunian et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study
Munther Khamashta et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Baricitinib in Patients with Refractory Rheumatoid Arthritis
Mark C. Genovese et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Vitamin D levels and cytokine profiles in patients with systemic lupus erythematosus
L. Schneider et al.
LUPUS (2015)
Genetic association analyses implicate aberrant regulation of innate and adaptive immunity genes in the pathogenesis of systemic lupus erythematosus
James Bentham et al.
NATURE GENETICS (2015)
Animal models of interferon signature positive lupus
Haoyang Zhuang et al.
FRONTIERS IN IMMUNOLOGY (2015)
A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-alpha monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients
Brandon W. Higgs et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Early, transient depletion of plasmacytoid dendritic cells ameliorates autoimmunity in a lupus model
Sarah L. Rowland et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
Genetic evidence for the role of plasmacytoid dendritic cells in systemic lupus erythematosus
Vanja Sisirak et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
Neutrophil-Mediated IFN Activation in the Bone Marrow Alters B Cell Development in Human and Murine Systemic Lupus Erythematosus
Arumugam Palanichamy et al.
JOURNAL OF IMMUNOLOGY (2014)
Epicutaneous Application of Toll-like Receptor 7 Agonists Leads to Systemic Autoimmunity in Wild-Type Mice
Maki Yokogawa et al.
ARTHRITIS & RHEUMATOLOGY (2014)
IFN and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus
Thomas Rose et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Sifalimumab, a Human AntiInterferon- Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose-Escalation Study
Michelle Petri et al.
ARTHRITIS AND RHEUMATISM (2013)
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
Gerd R. Burmester et al.
LANCET (2013)
Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus Results of a phase I, placebo-controlled, double-blind, dose-escalation study
Jacqueline M. McBride et al.
ARTHRITIS AND RHEUMATISM (2012)
Interferon regulatory factor 5 activation in monocytes of systemic lupus erythematosus patients is triggered by circulating autoantigens independent of type I interferons
Rivka C. Stone et al.
ARTHRITIS AND RHEUMATISM (2012)
The pathogenesis of systemic lupus erythematosus-an update
Jinyoung Choi et al.
CURRENT OPINION IN IMMUNOLOGY (2012)
Type I IFN Drives a Distinctive Dendritic Cell Maturation Phenotype That Allows Continued Class II MHC Synthesis and Antigen Processing
Daimon P. Simmons et al.
JOURNAL OF IMMUNOLOGY (2012)
Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort
R. Willis et al.
LUPUS (2012)
Phenotypic associations of genetic susceptibility loci in systemic lupus erythematosus
Elena Sanchez et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study
Joan T. Merrill et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Interferon-alpha Accelerates Murine Systemic Lupus Erythematosus in a T Cell-Dependent Manner
Zheng Liu et al.
ARTHRITIS AND RHEUMATISM (2011)
Identification of Novel Genetic Susceptibility Loci in African American Lupus Patients in a Candidate Gene Association Study
Elena Sanchez et al.
ARTHRITIS AND RHEUMATISM (2011)
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
Richard Furie et al.
ARTHRITIS AND RHEUMATISM (2011)
Activation of the type I interferon pathway in primary Sjogren's syndrome: an update
Katerina M. Vakaloglou et al.
CURRENT OPINION IN RHEUMATOLOGY (2011)
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
Sandra V. Navarra et al.
LANCET (2011)
Neutrophils Activate Plasmacytoid Dendritic Cells by Releasing Self-DNA-Peptide Complexes in Systemic Lupus Erythematosus
Roberto Lande et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Netting Neutrophils Are Major Inducers of Type I IFN Production in Pediatric Systemic Lupus Erythematosus
Gina S. Garcia-Romo et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Systemic Sclerosis and Lupus Points in an Interferon-Mediated Continuum
Shervin Assassi et al.
ARTHRITIS AND RHEUMATISM (2010)
Occupational and environmental exposures and risk of systemic lupus erythematosus: silica, sunlight, solvents
Glinda S. Cooper et al.
RHEUMATOLOGY (2010)
Lack of association between the interferon-α signature and longitudinal changes in disease activity in systemic lupus erythematosus
C. Landolt-Marticorena et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Potent Induction of IFN-α and Chemokines by Autoantibodies in the Cerebrospinal Fluid of Patients with Neuropsychiatric Lupus
Deanna M. Santer et al.
JOURNAL OF IMMUNOLOGY (2009)
Induction of autoimmunity by pristane and other naturally occurring hydrocarbons
Westley H. Reeves et al.
TRENDS IN IMMUNOLOGY (2009)
Systemic increase in type I interferon activity in Sjogren's syndrome: A putative role for plasmacytoid dendritic cells
Manon E. Wildenberg et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2008)
A novel type IIFN-producing cell subset in murine lupus
Pui Y. Lee et al.
JOURNAL OF IMMUNOLOGY (2008)
Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci
John B. Harley et al.
NATURE GENETICS (2008)
Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX
Geoffrey Hom et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Association of elevated transcript levels of interferon-inducible chemokines with disease activity and organ damage in systemic lupus erythematosus patients
Qiong Fu et al.
ARTHRITIS RESEARCH & THERAPY (2008)
Novel interferon-β-induced gene expression in peripheral blood cells
M. R. Sandhya Rani et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2007)
Deficiency of the type I interferon receptor protects mice from experimental lupus
Dina C. Nacionales et al.
ARTHRITIS AND RHEUMATISM (2007)
High serum IFN-α activity is a heritable risk factor for systemic lupus erythematosus
T. B. Niewold et al.
GENES AND IMMUNITY (2007)
Type I IFN contributes to NK cell homeostasis, activation, and antitumor function
Jeremy B. Swann et al.
JOURNAL OF IMMUNOLOGY (2007)
Lupus patients with pulmonary involvement have a pro-inflammatory cytokines profile
Sana Al-Mutairi et al.
RHEUMATOLOGY INTERNATIONAL (2007)
Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus
Robert R. Graham et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Identification of genes selectively regulated by IFNs in endothelial cells
Stefano Indraccolo et al.
JOURNAL OF IMMUNOLOGY (2007)
An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity
Emily C. Baechler et al.
MOLECULAR MEDICINE (2007)
Reproductive and menopausal factors and risk of systemic lupus erythematosus in women
Karen H. Costenbader et al.
ARTHRITIS AND RHEUMATISM (2007)
Type I IFN receptor signals directly stimulate local B cells early following influenza virus infection
Elizabeth S. Coro et al.
JOURNAL OF IMMUNOLOGY (2006)
Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection
GA Kolumam et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
A critical function for type I interferons in cancer immunoediting
GP Dunn et al.
NATURE IMMUNOLOGY (2005)
Cutting edge: Type IIFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation
JM Curtsinger et al.
JOURNAL OF IMMUNOLOGY (2005)
Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus
S Sigurdsson et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2005)
IFN-α induces early lethal lupus in preautoimmune (New Zealand black x New Zealand White)F1 but not in BALB/c mice
A Mathian et al.
JOURNAL OF IMMUNOLOGY (2005)
Induction of interferon-a production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late anoptotic cells and lupus IgG
T Lövgren et al.
ARTHRITIS AND RHEUMATISM (2004)
Comparative analysis of IRF and IFN-alpha expression in human plasmacytoid and monocyte-derived dendritic cells
A Izaguirre et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2003)
Differential responses to IFN-α subtypes in human T cells and dendritic cells
CMU Hilkens et al.
JOURNAL OF IMMUNOLOGY (2003)
Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator
KP Baker et al.
ARTHRITIS AND RHEUMATISM (2003)
Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice
ML Santiago-Raber et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus
EC Baechler et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Type I Interferon controls the onset and severity of autoimmune manifestations in lpr mice
D Braun et al.
JOURNAL OF AUTOIMMUNITY (2003)
Autoimmune disease complicating antiviral therapy for hepatitis C virus infection
LE Wilson et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2002)
Coordinated and distinct roles for IFN-αβ, IL-12, and IL-15 regulation of NK cell responses to viral infection
KB Nguyen et al.
JOURNAL OF IMMUNOLOGY (2002)
Induction of dendritic cell differentiation by IFN-α in systemic lupus erythematosus
P Blanco et al.
SCIENCE (2001)
Role of type I interferons during macrophage activation by lipopolysaccharide
PK Vadiveloo et al.
CYTOKINE (2000)
The combination of apoptotic U937 cells and lupus IgG is a potent IFN-α inducer
U Båve et al.
JOURNAL OF IMMUNOLOGY (2000)
Share Paper
